combined androgen blockade for the treatment of prostate cancer
... when using CAB. There is insufficient evidence to determine whether to start testosterone suppression when advance prostate cancer is detected or wait until symptoms develop, thereby sparing the patient of serious side effects (such as impotence). The evidence comparing adverse effects is limited, b ...
... when using CAB. There is insufficient evidence to determine whether to start testosterone suppression when advance prostate cancer is detected or wait until symptoms develop, thereby sparing the patient of serious side effects (such as impotence). The evidence comparing adverse effects is limited, b ...
a PowerPoint presentation detailing our
... ▫ Joel Kenney Professor of Medicine, and the Vice Dean for Cancer Medicine ▫ World famous expert in sphingolipid biochemistry ...
... ▫ Joel Kenney Professor of Medicine, and the Vice Dean for Cancer Medicine ▫ World famous expert in sphingolipid biochemistry ...
Prostate Cancer and Prostate-Specific Antigen
... 21. Twenty percent to 50 percent of men with benign 26. Screening proponents counter concerns of overdiagprostatic hypertrophy generally have modest FSA nosis by saying that the ability of PSA, DRE and TRUS to detect low-volume or latent cancer is limelevations. Occasionall~ BPH can cause markedly e ...
... 21. Twenty percent to 50 percent of men with benign 26. Screening proponents counter concerns of overdiagprostatic hypertrophy generally have modest FSA nosis by saying that the ability of PSA, DRE and TRUS to detect low-volume or latent cancer is limelevations. Occasionall~ BPH can cause markedly e ...
Advanced imaging techniques improve prostate
... About half of the men diagnosed with prostate cancer have low-risk tumors that make them good candidates for active surveillance: regular monitoring of prostatespecific antigen (PSA); annual biopsies; and a Gleason score, which grades cancer cells by how they look compared to normal cells. Active su ...
... About half of the men diagnosed with prostate cancer have low-risk tumors that make them good candidates for active surveillance: regular monitoring of prostatespecific antigen (PSA); annual biopsies; and a Gleason score, which grades cancer cells by how they look compared to normal cells. Active su ...
Pros and Cons of PSA Screening for Prostate Cancer
... fish, and soy products may provide protection. Eating a healthy diet is good advice for many other reasons as well! ...
... fish, and soy products may provide protection. Eating a healthy diet is good advice for many other reasons as well! ...
Cancer research in the Midland Region – the prostate and bowel
... control group that was not offered PSA screening (n=9952). • At the beginning of the study period, the PSA threshold used for diagnosing prostate cancer was 3.0 ng/mL of blood. For consistency with the European trial, in 1999 the diagnostic cut-off was changed to 2.9 ng/mL and in 2005 it was change ...
... control group that was not offered PSA screening (n=9952). • At the beginning of the study period, the PSA threshold used for diagnosing prostate cancer was 3.0 ng/mL of blood. For consistency with the European trial, in 1999 the diagnostic cut-off was changed to 2.9 ng/mL and in 2005 it was change ...
presentation by Professor Ross Lawrenson, Waikato Clinical School
... control group that was not offered PSA screening (n=9952). • At the beginning of the study period, the PSA threshold used for diagnosing prostate cancer was 3.0 ng/mL of blood. For consistency with the European trial, in 1999 the diagnostic cut-off was changed to 2.9 ng/mL and in 2005 it was changed ...
... control group that was not offered PSA screening (n=9952). • At the beginning of the study period, the PSA threshold used for diagnosing prostate cancer was 3.0 ng/mL of blood. For consistency with the European trial, in 1999 the diagnostic cut-off was changed to 2.9 ng/mL and in 2005 it was changed ...
Prostate Pathology
... Staging in prostate cancer depends on the TNM system. It is the most important indicator of prognosis. ...
... Staging in prostate cancer depends on the TNM system. It is the most important indicator of prognosis. ...
impact of low prostate specific antigen on prostate
... technique provides only a limited amount of tissue. Thus, it is not surprising that the correlation between biopsy and final pathology, tumor volume and Gleason grade might be considered rather poor, and the potential aggressiveness of a small lesion can be underestimated [16]. Additionally, a recen ...
... technique provides only a limited amount of tissue. Thus, it is not surprising that the correlation between biopsy and final pathology, tumor volume and Gleason grade might be considered rather poor, and the potential aggressiveness of a small lesion can be underestimated [16]. Additionally, a recen ...
Does screening for Prostate Cancer save lives? ERSPC
... *5-year relative survival rates based on follow up of patients through 2003. †Recent changes in classification of ovarian cancer have affected 1996-2002 survival rates. Source: Surveillance, Epidemiology, and End Results Program, 1975-2003, Division of Cancer Control and ...
... *5-year relative survival rates based on follow up of patients through 2003. †Recent changes in classification of ovarian cancer have affected 1996-2002 survival rates. Source: Surveillance, Epidemiology, and End Results Program, 1975-2003, Division of Cancer Control and ...
The Supportive Care Needs of Men With Advanced Prostate Cancer
... cancer in Canadian men and accounts for 27% of all cancer cases (Canadian Cancer Society and National Cancer Institute of Canada, 2010). Despite improvements in early detection and treatment, many men progress from localized to advanced disease. Advanced prostate cancer is a chronic condition requir ...
... cancer in Canadian men and accounts for 27% of all cancer cases (Canadian Cancer Society and National Cancer Institute of Canada, 2010). Despite improvements in early detection and treatment, many men progress from localized to advanced disease. Advanced prostate cancer is a chronic condition requir ...
OVER 50 AND DIAGNOSED WITH PROSTATE CANCER?
... with 50 per cent of those having nothing. This difference is not deemed statistically significant. However, importantly, men who choose to do nothing are only half as likely to suffer from urinary incontinence or erectile dysfunction. ...
... with 50 per cent of those having nothing. This difference is not deemed statistically significant. However, importantly, men who choose to do nothing are only half as likely to suffer from urinary incontinence or erectile dysfunction. ...
Treatment options for men with localised prostate cancer
... prostate cancer most commonly arises. Although preserving these nerves at the time of surgery may be possible, it is not always wise. The less tissue removed around the prostate, the greater the chance that cancer cells will remain. Since the primary goal of the operation is to remove all of the can ...
... prostate cancer most commonly arises. Although preserving these nerves at the time of surgery may be possible, it is not always wise. The less tissue removed around the prostate, the greater the chance that cancer cells will remain. Since the primary goal of the operation is to remove all of the can ...
Cabazitaxel has been approved in the United States for second
... New Chemo Approved for Advanced Prostate Cancer ...
... New Chemo Approved for Advanced Prostate Cancer ...
Targeting device for high precision radiation theraphy of prostate
... avoiding complications in sensitive organs and tissues adjacent to the prostate. ...
... avoiding complications in sensitive organs and tissues adjacent to the prostate. ...